Ermenegildo Zegna NV
ZGN
Workday
WDAY
Dorian LPG
LPG
DexCom
DXCM
Precision Drilling
PDS
US Stock MarketDetailed Quotes
ANEB Anebulo Pharmaceuticals
- 1.620
- +0.370+29.60%
Close Dec 24 13:00 ET
66.56MMarket Cap-5.40P/E (TTM)
1.690High1.100Low91.05KVolume1.100Open1.250Pre Close134.34KTurnover0.48%Turnover RatioLossP/E (Static)41.08MShares3.30052wk High35.22P/B30.88MFloat Cap0.80052wk Low--Dividend TTM19.06MShs Float9.330Historical High--Div YieldTTM47.20%Amplitude0.800Historical Low1.475Avg Price1Lot Size
Anebulo Pharmaceuticals News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Anebulo Pharmaceuticals Collaborates With FDA to Advance Selonabant
Express News | Anebulo Pharmaceuticals: Intends to Modify Loan and Security Agreement by Reducing Maximum Loan Size to About $3 Mln
Express News | Anebulo Pharmaceuticals: Entered Stock Purchase Agreement for Issuance & Sale of 15.2 Mln Shares of Common Stock for $15 Mln
Anebulo Pharmaceuticals Announces FDA Feedback For IV Selonabant To Address Cannabis-Induced Toxicity In Children And Completes $15M Capital Raise; Phase I Study Planned For 1H25
Express News | Anebulo Pharmaceuticals Inc: Plans to Begin Its Phase I Sad Study of IV Selonabant in Healthy Adults in 1H25
Express News | Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Anebulo Pharmaceuticals Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q1 EPS Results.
Anebulo Pharmaceuticals | 10-Q: Q1 2025 Earnings Report
Anebulo Pharmaceuticals | 8-K: Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
Benchmark Co. Maintains Anebulo Pharmaceuticals(ANEB.US) With Buy Rating, Maintains Target Price $8
Express News | Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals | 10-K: FY2024 Annual Report
Anebulo Pharmaceuticals | 8-K: Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports Q4 EPS (5c) Vs. (10c) Last Year
Express News | Anebulo Pharmaceuticals, Inc. Q4 Operating Expenses USD 1.3 Million
Anebulo Pharmaceuticals 4Q Loss/Shr 5c >ANEB
Express News | Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Top Premarket Decliners
